News & Updates

Show Multimedia Only

Pfizer's COVID-19 antiviral pills yield EPIC results for hospitalization, deaths

19 Dec 2021 by

A new oral COVID-19 antiviral therapy comprising nirmatrelvir and ritonavir substantially slashes the risk of hospitalization or death compared with placebo in nonhospitalized adults with COVID-19 who are at high risk of developing severe illness, according to final analysis of the EPIC-HR* study.

19 Dec 2021

Reduced kidney function, urine output tied to kidney nonrecovery in COVID-19 patients

19 Dec 2021

Among critically ill patients with COVID-19, those who present with lower baseline estimated glomerular filtration rate (eGFR) and reduced urine output at the time of kidney replacement therapy (KRT) initiation are more likely to experience kidney nonrecovery, according to a study.

19 Dec 2021

Former smokers with COVID-19 face higher risk of death

17 Dec 2021

In a cohort of veterans with COVID-19, former smokers are at higher risk of 30-day mortality compared with current smokers and nonsmokers, as reported in a study.

17 Dec 2021

No benefit from adding interferon beta-1a to remdesivir in COVID-19

16 Dec 2021 by

Adding interferon beta-1a to remdesivir did not hasten time to recovery among adults hospitalized with COVID-19, according to results of the phase III ACTT*-3 trial.

16 Dec 2021

Certain IBD meds tied to excess risk of COVID-19 hospitalization

16 Dec 2021 by

While there are no differences in COVID-19-related outcomes in patients with inflammatory bowel disease (IBD) between those in remission vs those who are not, being on medications such as corticosteroids and aminosalicylates may put them at higher risk of hospitalization, suggest studies presented at AIBD 2021.

16 Dec 2021

Diabetes not a risk factor for long COVID

16 Dec 2021 by

Diabetes does not appear to predispose SARS-CoV-2–infected patients to long-term post-COVID-19 symptoms, a study reports.

16 Dec 2021

Immune memory persistent but exhausted 1 year after COVID-19

16 Dec 2021 by

In convalescent patients with the coronavirus disease 2019 (COVID-19), humoral and cellular responses against the SARS-CoV-2 virus remain robust at 1 year after infection, according to a recent study. However, a notable dysfunction in CD4+ T cells emphasizes the need for vaccination to prevent reinfection.

16 Dec 2021

Entecavir prevents HBV reactivation in individuals on DAA for HCV/HBV dual infection

15 Dec 2021

For patients undergoing direct acting antiviral (DAA) therapy for hepatitis C virus (HCV)/hepatitis B virus (HBV) dual infection, cotreatment with entecavir helps avert reactivation of HBV, as shown in a study.

15 Dec 2021